Midazolam
| Evidence Level: L2 | Predicted Indications: 1 |
Table of Contents
Midazolam: From Procedural Sedation to Insomnia
One-Sentence Summary
Midazolam is a short-acting benzodiazepine most familiar in current practice as a sedative for medical procedures and anaesthesia premedication. The TxGNN model predicts it may also be effective for Insomnia, with 2 directly relevant clinical trials and 10 supporting publications (including four RCTs) currently available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Procedural sedation / anaesthesia premedication (short-acting benzodiazepine; not detailed in the evidence pack) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L2 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacology, midazolam is a benzodiazepine that acts as a positive allosteric modulator at the GABA-A receptor, producing sedative and hypnotic effects — the same mechanistic class as already-approved hypnotics such as flurazepam and zolpidem. This shared receptor pharmacology provides a plausible theoretical basis for the TxGNN prediction linking midazolam to insomnia.
However, the mechanistic rationale is tempered by pharmacokinetic and regulatory concerns. Midazolam’s ultra-short elimination half-life (approximately 1.5–2.5 hours) makes it prone to next-day rebound insomnia and inconsistent overnight sedation — either insufficient residual effect or excessive daytime carry-over. It is also a Schedule 4 controlled drug, and long-term use carries recognised risks of tolerance, dependence, and respiratory depression. For these reasons, clinical practice has largely moved toward hypnotics with more favourable half-lives and lower dependence liability (e.g. zolpidem, lemborexant) for chronic insomnia management.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT06407518 | NA | Recruiting | 280 | Randomised, double-blind, placebo-controlled trial of preoperative oral midazolam in patients with sleep disturbance/anxiety undergoing laparoscopic colorectal cancer resection; midazolam oral solution reported as safe and effective for short-term hypnosis, though insomnia is not the primary efficacy endpoint. |
| NCT02142595 | Phase 4 | Completed | 111 | Compared postoperative sleep quality with IV dexmedetomidine versus midazolam combined with spinal anaesthesia in patients undergoing TURP; provides indirect supportive data on midazolam’s effect on sleep quality in a postoperative (not chronic insomnia) population. |
| NCT01966315 | NA | Terminated (N=5) | 5 | Compared sleep quality/quantity (24-hour polysomnography) and delirium incidence between dexmedetomidine and midazolam in mechanically ventilated ICU patients; terminated early with very small sample size, limiting interpretability. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 6138072 | 1983 | RCT | Br J Clin Pharmacol | Double-blind study of midazolam 15 mg vs Vesparax in 30 women with insomnia secondary to neuromuscular disease; midazolam was an effective hypnotic, better tolerated, and did not cause hangover effects. |
| 2121802 | 1990 | RCT | J Clin Psychopharmacol | Multicentre randomised, double-blind, parallel-group study of sleep, performance and plasma levels during 14-day use of flurazepam vs midazolam in chronic insomniacs. |
| 6120704 | 1981 | RCT | Arzneimittel-Forschung | Dose-finding pilot study (10–30 mg oral midazolam) in 75 hospitalised patients with mild-to-moderate insomnia secondary to musculoskeletal disorders, peripheral nerve disease and allergies; established an optimal dose range. |
| 2229461 | 1990 | RCT | J Clin Psychopharmacol | Executive summary of the multicentre 14-day flurazepam vs midazolam study in chronic insomniacs (companion paper to PMID 2121802). |
| 2883820 | 1986 | Review | Acta Psychiatr Scand Suppl | Reviews the clinical use of hypnotics across benzodiazepine classes, discussing indications and the rationale for a variety of agents with differing pharmacokinetic profiles. |
| 17988972 | 2007 | Review | Orvosi Hetilap | General review of insomnia pathogenesis, including the hyperarousal hypothesis and classification of primary vs secondary insomnia. |
| 36615100 | 2022 | Review | J Clin Med | Pilot study/review noting that benzodiazepines (including midazolam) have traditionally been used for insomnia but may increase delirium risk in high-risk patients undergoing sedation. |
| 22729271 | 2013 | Preclinical | Psychopharmacology | Preclinical study of the hypnotic zolpidem on sedation, anxiety and memory, relevant to benzodiazepine-class hypnotic pharmacology. |
| 21396773 | 2011 | Preclinical | Pain | Mouse model study linking neuropathic pain-related sleep disturbance to altered GABAergic transmission, supporting the GABA-A mechanistic link to sleep regulation. |
| 36912148 | 2024 | Case Report | Am J Hosp Palliat Care | Case discussion of symptom management, including sedative use, at end of life in COVID-19 patients. |
UK Market Information
Midazolam currently has no marketing authorisation records in the evidence pack and is listed as Not Marketed for this indication pathway. No product-level licence, brand name, or formulation data is available for review.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(No specific warnings, contraindications, or drug interaction data were available in the evidence pack for this assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale (GABA-A agonism, shared class with approved hypnotics) is sound and supported by several older RCTs showing efficacy in short-term insomnia, but the evidence base is dated (1980s–1990s), lacks trials in the target chronic-insomnia population using modern outcome measures, and is undermined by midazolam’s pharmacokinetic drawbacks (ultra-short half-life, rebound insomnia risk) and its status as a Schedule 4 controlled drug. Critically, no UK SmPC-level warnings, contraindications, or DDI data were available, which blocks a safety-stage (S1) assessment.
To proceed, the following is needed:
- MHRA/SmPC-level warnings, contraindications and drug interaction data for midazolam (currently a blocking data gap)
- Detailed mechanism of action documentation to support formal mechanistic-relevance scoring
- A contemporary RCT or systematic review specifically evaluating midazolam (vs. current standard hypnotics) in chronic insomnia populations
- Assessment of controlled-drug scheduling implications for a new insomnia indication in the UK
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.